Pages that link to "Q45000633"
Jump to navigation
Jump to search
The following pages link to Lipid-lowering response to statins is affected by CYP3A5 polymorphism (Q45000633):
Displaying 50 items.
- Pharmacogenomics of statins: understanding susceptibility to adverse effects (Q28079822) (← links)
- Pharmacogenetics of erectile dysfunction: navigating into uncharted waters (Q28249515) (← links)
- Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests (Q28260518) (← links)
- Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins (Q28276232) (← links)
- A gene score of nine LDL and HDL regulating genes is associated with fluvastatin-induced cholesterol changes in women (Q33634188) (← links)
- Candidate-Gene Study of Functional Polymorphisms in SLCO1B1 and CYP3A4/5 and the Cholesterol-Lowering Response to Simvastatin (Q33648028) (← links)
- Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes (Q33690357) (← links)
- Evaluation of sexual dimorphism in the efficacy and safety of simvastatin/atorvastatin therapy in a southern Brazilian cohort (Q34020658) (← links)
- CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort (Q34160942) (← links)
- Statins and breast cancer prognosis: evidence and opportunities. (Q34206487) (← links)
- Mapping genes that predict treatment outcome in admixed populations (Q34348337) (← links)
- Lactase persistence and lipid pathway selection in the Maasai (Q34427355) (← links)
- Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel (Q34568130) (← links)
- Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins (Q34680467) (← links)
- Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin (Q34787395) (← links)
- Pharmacogenomics: the genetics of variable drug responses (Q34976915) (← links)
- Pharmacogenomic Biomarkers for the Prediction of Statin Efficacy and Safety (Q35158967) (← links)
- The emerging role of electronic medical records in pharmacogenomics (Q35478918) (← links)
- Sex differences in the effectiveness of statins after myocardial infarction. (Q35607051) (← links)
- Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs (Q35642257) (← links)
- A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system (Q35826448) (← links)
- A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers. (Q35917726) (← links)
- CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin (Q35933626) (← links)
- Statin response and pharmacokinetics variants (Q36192738) (← links)
- Pharmacogenomics of cholesterol-lowering therapy (Q36335716) (← links)
- Clinical implications of pharmacogenomics of statin treatment (Q36426816) (← links)
- A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer (Q36507085) (← links)
- Clinical implications of CYP3A polymorphisms (Q36546247) (← links)
- Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population. (Q36577254) (← links)
- The independent contribution of miRNAs to the missing heritability in CYP3A4/5 functionality and the metabolism of atorvastatin (Q36925256) (← links)
- CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control (Q36927210) (← links)
- Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. (Q37017426) (← links)
- Pharmacogenetics of response to statins (Q37074291) (← links)
- PharmGKB summary: very important pharmacogene information for CYP3A5. (Q37081741) (← links)
- No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin (Q37399440) (← links)
- Pharmacogenomics of CYP3A: considerations for HIV treatment (Q37419542) (← links)
- Statin regulation of CYP3A4 and CYP3A5 expression (Q37521064) (← links)
- Genetic determinants of response to statins (Q37578563) (← links)
- HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice (Q37608527) (← links)
- Impact of CYP3A5 Gene Polymorphism on Efficacy of Simvastatin (Q37646573) (← links)
- Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity? (Q37733572) (← links)
- Clinical implications of pharmacogenetic variation on the effects of statins. (Q37818151) (← links)
- Clinical response to statins: mechanism(s) of variable activity and adverse effects (Q37881964) (← links)
- Statin dose in Asians: is pharmacogenetics relevant? (Q37951651) (← links)
- Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes (Q37964574) (← links)
- Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations (Q38086777) (← links)
- Lipid-lowing pharmacogenomics in Chinese patients (Q38129422) (← links)
- Drug-drug interactions that interfere with statin metabolism (Q38522299) (← links)
- Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments (Q38644870) (← links)
- Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia. (Q38663481) (← links)